MedTrace Logo

Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00618345 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2011-05-16

No results posted yet for this study

Summary

RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.

PURPOSE: This phase II trial is studying how well everolimus works in treating patients with relapsed or refractory multiple myeloma.

Conditions

  • Multiple Myeloma and Plasma Cell Neoplasm

Interventions

DRUG

everolimus

GENETIC

DNA analysis

GENETIC

protein analysis

GENETIC

western blotting

OTHER

flow cytometry

OTHER

laboratory biomarker analysis

PROCEDURE

biopsy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Thomas E. Witzig, MD · Mayo Clinic

  • Rafael Fonseca, MD · Mayo Clinic

  • Roy Vivek, MD · Mayo Clinic

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2006-10-31
Completion
2008-08-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00618345 on ClinicalTrials.gov